LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Amphastar Pharmaceuticals Inc

Abrir

SetorSaúde

23.15 -0.43

Visão Geral

Variação de preço das ações

24h

Atual

Mín

23.01

Máximo

23.39

Indicadores-chave

By Trading Economics

Rendimento

-13M

25M

Vendas

-16M

171M

P/E

Médio do Setor

8.899

50.291

EPS

0.74

Margem de lucro

14.827

Funcionários

2,028

EBITDA

-13M

52M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+33.6% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-6.1M

1.2B

Abertura anterior

23.58

Fecho anterior

23.15

Sentimento de Notícias

By Acuity

50%

50%

154 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Amphastar Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de jun. de 2025, 23:49 UTC

Ganhos

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 de jun. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 de jun. de 2025, 21:30 UTC

Ganhos

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 de jun. de 2025, 21:07 UTC

Ganhos

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 de jun. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 de jun. de 2025, 23:39 UTC

Conversa de Mercado

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 de jun. de 2025, 23:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 de jun. de 2025, 23:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 de jun. de 2025, 23:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 de jun. de 2025, 23:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 de jun. de 2025, 23:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 de jun. de 2025, 23:31 UTC

Aquisições, Fusões, Aquisições de Empresas

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 de jun. de 2025, 23:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 de jun. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 de jun. de 2025, 23:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 de jun. de 2025, 22:06 UTC

Ganhos

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 de jun. de 2025, 21:15 UTC

Ganhos

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 de jun. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 de jun. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 de jun. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 de jun. de 2025, 21:07 UTC

Ganhos

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 de jun. de 2025, 21:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 de jun. de 2025, 21:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 de jun. de 2025, 21:06 UTC

Conversa de Mercado

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 de jun. de 2025, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 de jun. de 2025, 21:05 UTC

Aquisições, Fusões, Aquisições de Empresas

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 de jun. de 2025, 20:52 UTC

Ganhos

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 de jun. de 2025, 20:51 UTC

Ganhos

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Amphastar Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

33.6% parte superior

Previsão para 12 meses

Média 31.33 USD  33.6%

Máximo 35 USD

Mínimo 29 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Amphastar Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

1

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

23.91 / 25.04Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

154 / 380 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.